CONCLUSIONS: Although infliximab and vedolizumab have similar efficacy in clinical symptom improvement, infliximab had higher rates of one-year corticosteroid-free CR and ER in treatment of biologic-naïve UC.

Full Text Link: https://libkey.io/34329776?utm_source=ibdwatch